Literature DB >> 20181335

Coronary flow reserve is impaired in patients with nonalcoholic fatty liver disease: association with liver fibrosis.

Yusuf Yilmaz1, Ramazan Kurt, Oya Yonal, Nihat Polat, Cigdem Ataizi Celikel, Ahmet Gurdal, Huseyin Oflaz, Osman Ozdogan, Nese Imeryuz, Cem Kalayci, Erol Avsar.   

Abstract

BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is associated with an increased risk of cardiovascular disease. Coronary flow reserve (CFR) is widely used to examine the integrity of coronary microvascular circulation. We evaluated the prevalence of impaired CFR in patients with biopsy-proven NAFLD. We also investigated the independent clinical, biochemical, and liver histology predictors of CFR in the setting of NAFLD.
METHODS: Fifty-nine consecutive patients with NAFLD and 77 age- and gender-matched controls were evaluated. CFR recordings were performed by transthoracic Doppler harmonic echocardiography. CFR>or=2.0 was considered normal.
RESULTS: CFR was significantly lower in patients with NAFLD than in controls (2.11+/-0.45 vs. 2.52+/-0.62, P<0.001). An impaired CFR (i.e. <2) was found in 25 NAFLD patients (42.4%) whereas all controls had normal CFR values (P<0.001). A stepwise linear regression analysis in NAFLD patients identified liver fibrosis scores as the only independent predictor of CFR values (beta=-0.60; t=-2.44, P=0.021).
CONCLUSION: Our findings indicate that in patients with biopsy-proven NAFLD: (a) an abnormal CFR is found in approximately 42.4% of cases, and (b) liver fibrosis scores are an independent predictor of depressed CFR. Copyright (c) 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20181335     DOI: 10.1016/j.atherosclerosis.2010.01.049

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  32 in total

Review 1.  Composite prognostic models across the non-alcoholic fatty liver disease spectrum: Clinical application in developing countries.

Authors:  Hilmar K Lückhoff; Frederik C Kruger; Maritha J Kotze
Journal:  World J Hepatol       Date:  2015-05-28

Review 2.  Role of cardiovascular intervention as a bridge to liver transplantation.

Authors:  Zankhana Raval; Matthew E Harinstein; James D Flaherty
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

Review 3.  The Role of Non-alcoholic Fatty Liver Disease in Cardiovascular Disease.

Authors:  Sven M Francque
Journal:  Eur Cardiol       Date:  2014-07

Review 4.  Non-alcoholic fatty liver disease: A growing public health problem in Turkey.

Authors:  Eda Kaya; Yusuf Yılmaz
Journal:  Turk J Gastroenterol       Date:  2019-10       Impact factor: 1.852

Review 5.  Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease.

Authors:  Stefano Ballestri; Amedeo Lonardo; Stefano Bonapace; Christopher D Byrne; Paola Loria; Giovanni Targher
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

Review 6.  Cardiovascular Disease and Myocardial Abnormalities in Nonalcoholic Fatty Liver Disease.

Authors:  Alessandro Mantovani; Stefano Ballestri; Amedeo Lonardo; Giovanni Targher
Journal:  Dig Dis Sci       Date:  2016-01-25       Impact factor: 3.199

7.  Multidisciplinary approach to cardiac and pulmonary vascular disease risk assessment in liver transplantation: An evaluation of the evidence and consensus recommendations.

Authors:  Lisa B VanWagner; Matthew E Harinstein; James R Runo; Christopher Darling; Marina Serper; Shelley Hall; Jon A Kobashigawa; Laura L Hammel
Journal:  Am J Transplant       Date:  2017-11-18       Impact factor: 8.086

Review 8.  Nonalcoholic fatty liver disease and vascular disease: state-of-the-art.

Authors:  Silvia Fargion; Marianna Porzio; Anna Ludovica Fracanzani
Journal:  World J Gastroenterol       Date:  2014-10-07       Impact factor: 5.742

9.  One-year GH replacement therapy reduces early cardiac target organ damage (TOD) in adult GHD patients.

Authors:  Mara Boschetti; Sergio Agosti; Valeria Albanese; Laura Casalino; Claudia Teti; Gian Paolo Bezante; Claudio Brunelli; Manuela Albertelli; Diego Ferone
Journal:  Endocrine       Date:  2016-04-13       Impact factor: 3.633

Review 10.  Cardiovascular Risk Reduction in Patients with Nonalcoholic Fatty Liver Disease: The Potential Role of Ezetimibe.

Authors:  Tracey G Simon; Kathleen E Corey; Raymond T Chung; Robert Giugliano
Journal:  Dig Dis Sci       Date:  2016-10-06       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.